Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

• Status: Completed
• Trial end date: 2021-04-28
• Target enrollment: 0
• Participant gender: All

Summary

This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Chinese patients

• Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints

• Active plaque psoriasis at screening

• Inadequate response to at least one conventional synthetic DMARD

Exclusion Criteria:

• Non-plaque forms of psoriasis (with exception of nail psoriasis)

• History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA